共 89 条
Thalidomide and immunomodulatory drugs in the treatment of cancer
被引:23
作者:

Bamias, A
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Athens, Sch Med, Dept Clin Therapeut, Athens 14561, Greece Univ Athens, Sch Med, Dept Clin Therapeut, Athens 14561, Greece

Dimopoulos, MA
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Athens, Sch Med, Dept Clin Therapeut, Athens 14561, Greece Univ Athens, Sch Med, Dept Clin Therapeut, Athens 14561, Greece
机构:
[1] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 14561, Greece
关键词:
angiogenesis;
cancer;
CC-4047;
CC-5013;
ImiD;
myeloma;
thalidomide;
D O I:
10.1517/13543784.14.1.45
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies. Multiple studies have confirmed its activity in multiple myeloma, alone or combined with dexamethasone and/or chemotherapy as first- or second-line treatment. In addition, it may reduce the need for transfusions in patients with myelofibrosis or myelodysplastic syndromes. The activity of thalidomide in solid tumours is less prominent. The most promising results have been reported in Kaposi's sarcoma, malignant melanoma and prostate cancer, especially when it is combined with chemotherapy. Recently, thalidomide analogues (immunomodulatory drugs), with higher immunomodulatory activity and different toxicity profile, have been developed. They have already shown promising activity in multiple myeloma and are currently being evaluated in clinical studies.
引用
收藏
页码:45 / 55
页数:11
相关论文
共 89 条
[1]
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy
[J].
Alexanian, R
;
Weber, D
;
Giralt, S
;
Delasalle, K
.
ANNALS OF ONCOLOGY,
2002, 13 (07)
:1116-1119

Alexanian, R
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

Weber, D
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

Giralt, S
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

Delasalle, K
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2]
Phase II evaluation of thalidomide in patients with metastatic breast cancer
[J].
Baidas, SM
;
Winer, EP
;
Fleming, GF
;
Harris, L
;
Pluda, JM
;
Crawford, JG
;
Yamauchi, H
;
Isaacs, C
;
Hanfelt, J
;
Tefft, M
;
Flockhart, D
;
Johnson, MD
;
Hawkins, MJ
;
Lippman, ME
;
Hayes, DF
.
JOURNAL OF CLINICAL ONCOLOGY,
2000, 18 (14)
:2710-2717

Baidas, SM
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Winer, EP
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Fleming, GF
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Harris, L
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Pluda, JM
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Crawford, JG
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Yamauchi, H
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Isaacs, C
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Hanfelt, J
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Tefft, M
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Flockhart, D
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Johnson, MD
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Hawkins, MJ
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Lippman, ME
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA

Hayes, DF
论文数: 0 引用数: 0
h-index: 0
机构: Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Breast Canc Program, Washington, DC 20007 USA
[3]
Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience
[J].
Barlogie, B
.
SEMINARS IN HEMATOLOGY,
2003, 40 (04)
:33-38

Barlogie, B
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[4]
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
[J].
Barlogie, B
;
Desikan, R
;
Eddlemon, P
;
Spencer, T
;
Zeldis, J
;
Munshi, N
;
Badros, A
;
Zangari, M
;
Anaissie, E
;
Epstein, J
;
Shaughnessy, J
;
Ayers, D
;
Spoon, D
;
Tricot, G
.
BLOOD,
2001, 98 (02)
:492-494

Barlogie, B
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Desikan, R
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Eddlemon, P
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Spencer, T
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Zeldis, J
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Munshi, N
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Badros, A
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Zangari, M
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Anaissie, E
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Epstein, J
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Shaughnessy, J
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Ayers, D
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Spoon, D
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

Tricot, G
论文数: 0 引用数: 0
h-index: 0
机构: Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA
[5]
Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
[J].
Bartlett, JB
;
Michael, A
;
Clarke, IA
;
Dredge, K
;
Nicholson, S
;
Kristeleit, H
;
Polychronis, A
;
Pandha, H
;
Muller, GW
;
Stirling, DI
;
Zeldis, J
;
Dalgleish, AG
.
BRITISH JOURNAL OF CANCER,
2004, 90 (05)
:955-961

Bartlett, JB
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Michael, A
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Clarke, IA
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Dredge, K
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Nicholson, S
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Kristeleit, H
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Polychronis, A
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Pandha, H
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Muller, GW
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Stirling, DI
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Zeldis, J
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England

Dalgleish, AG
论文数: 0 引用数: 0
h-index: 0
机构: St George Hosp, Sch Med, Dept Cellular & Mol Med, Div Oncol, London SW17 0RE, England
[6]
Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme
[J].
Baumann, F
;
Bjeljac, M
;
Kollias, SS
;
Baumert, BG
;
Brandner, S
;
Rousson, V
;
Yonekawa, Y
;
Bernays, RL
.
JOURNAL OF NEURO-ONCOLOGY,
2004, 67 (1-2)
:191-200

Baumann, F
论文数: 0 引用数: 0
h-index: 0
机构: Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland

Bjeljac, M
论文数: 0 引用数: 0
h-index: 0
机构: Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland

Kollias, SS
论文数: 0 引用数: 0
h-index: 0
机构: Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland

Baumert, BG
论文数: 0 引用数: 0
h-index: 0
机构: Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland

Brandner, S
论文数: 0 引用数: 0
h-index: 0
机构: Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland

论文数: 引用数:
h-index:
机构:

Yonekawa, Y
论文数: 0 引用数: 0
h-index: 0
机构: Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland

Bernays, RL
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland
[7]
Thalidomide in patients with cachexia due to terminal cancer: Preliminary report
[J].
Bruera, E
;
Neumann, CM
;
Pituskin, E
;
Calder, K
;
Ball, G
;
Hanson, J
.
ANNALS OF ONCOLOGY,
1999, 10 (07)
:857-859

Bruera, E
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada

Neumann, CM
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada

Pituskin, E
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada

Calder, K
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada

Ball, G
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada

Hanson, J
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada Univ Alberta, Cross Canc Ctr, Div Palliat Care Med, Edmonton, AB, Canada
[8]
Thalidomide in multiple myeloma: Current status and future prospects
[J].
Cavenagh, JD
;
Oakervee, H
.
BRITISH JOURNAL OF HAEMATOLOGY,
2003, 120 (01)
:18-26

Cavenagh, JD
论文数: 0 引用数: 0
h-index: 0
机构:
St Bartholomews & Royal London Sch Med & Dent, London, England St Bartholomews & Royal London Sch Med & Dent, London, England

Oakervee, H
论文数: 0 引用数: 0
h-index: 0
机构:
St Bartholomews & Royal London Sch Med & Dent, London, England St Bartholomews & Royal London Sch Med & Dent, London, England
[9]
Thalidomide-induced neuropathy
[J].
Chaudhry, V
;
Cornblath, DR
;
Corse, A
;
Freimer, M
;
Simmons-O'Brien, E
;
Vogelsang, G
.
NEUROLOGY,
2002, 59 (12)
:1872-1875

Chaudhry, V
论文数: 0 引用数: 0
h-index: 0
机构: Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

Cornblath, DR
论文数: 0 引用数: 0
h-index: 0
机构: Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

Corse, A
论文数: 0 引用数: 0
h-index: 0
机构: Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

Freimer, M
论文数: 0 引用数: 0
h-index: 0
机构: Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

Simmons-O'Brien, E
论文数: 0 引用数: 0
h-index: 0
机构: Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

Vogelsang, G
论文数: 0 引用数: 0
h-index: 0
机构: Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[10]
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
[J].
Cortes, J
;
Kantarjian, H
;
Albitar, M
;
Thomas, D
;
Faderl, S
;
Koller, C
;
Garcia-Manero, G
;
Giles, F
;
Andreeff, M
;
O'Brien, S
;
Keating, M
;
Estey, E
.
CANCER,
2003, 97 (05)
:1234-1241

Cortes, J
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Kantarjian, H
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Albitar, M
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Thomas, D
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Faderl, S
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Koller, C
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Garcia-Manero, G
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Giles, F
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Andreeff, M
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

O'Brien, S
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Keating, M
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

Estey, E
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA